share_log

Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $90

Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $90

羅斯資本維持對配體製藥的買入,將目標價格提高至 90 美元
Benzinga Real-time News ·  2022/12/23 07:44

Roth Capital analyst Scott Henry maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $85 to $90.

Roth Capital分析師斯科特·亨利維持納斯達克(Ligand PharmPharmticals)的買入,並將目標價從85美元上調至90美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論